Tag: CX 2022

Sirogen™: A potential solution for improving arteriovenous fistula maturation

This advertorial is sponsored by Vascular Therapies Arteriovenous fistula (AVF) maturation is a pivotal event in patients requiring haemodialysis. Maximising the number of fistulas that...

New sirolimus data provide encouragement despite “potentially disappointing” efficacy results

The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access...

IN.PACT AV DCB “first and only” to show sustained and superior...

Medtronic has announced new randomised controlled data demonstrating the sustained and superior performance of the IN.PACT AV drug-coated balloon (DCB) compared to percutaneous transluminal...

Restorative Axess graft demonstrates promising patency and safety in first-in-human study

The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...

CX returns to in-person format once more in the London spring

Charing Cross (CX) chair Roger Greenhalgh welcomes the vascular community to this year's symposium, due to be held 26–28 April in London, UK, and...

CX 2022: Nicholas Inston on Vascular Access Challenges

 Nicholas Inston (Birmingham, UK) talks to CX about the challenges in creation, maintenance and salvage of vascular access in patients with end stage renal disease....